---
id: esmo-nsclc-metastatic-2023
title: "Non-oncogene-addicted Metastatic Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guideline"
short_title: "ESMO Metastatic NSCLC 2023"

organization: European Society for Medical Oncology
collaborators: null
country: null
url: https://www.esmo.org/guidelines/guidelines-by-topic/esmo-clinical-practice-guidelines-lung-and-chest-tumours
doi: 10.1016/j.annonc.2022.12.013
pmid: 36669645
open_access: true

specialty: oncology
guideline_type: clinical-practice
evidence_system: other
conditions:
  - non-small cell lung cancer
  - metastatic NSCLC
  - lung adenocarcinoma
  - squamous cell lung cancer
tags:
  - immunotherapy
  - PD-L1
  - pembrolizumab
  - chemotherapy
  - first-line therapy
  - biomarker testing

publication_date: 2023-01-17
previous_version_date: 2018-09-27
status: current
supersedes: esmo-nsclc-metastatic-2018
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-21
---

## Scope

Diagnosis, treatment, and follow-up of metastatic non-small cell lung cancer without actionable oncogenic drivers, including biomarker testing, first-line and subsequent therapy, and supportive care.

## Notes

Focuses on non-oncogene-addicted mNSCLC. Separate ESMO guidelines exist for oncogene-addicted mNSCLC (EGFR, ALK, ROS1, etc.) and early/locally advanced NSCLC.
